Rhumbline Advisers increased its position in Minerva Neurosciences Inc (NASDAQ:NERV) by 48.3% in the 4th quarter, Holdings Channel reports. The fund owned 40,909 shares of the biopharmaceutical company’s stock after purchasing an additional 13,332 shares during the period. Rhumbline Advisers’ holdings in Minerva Neurosciences were worth $276,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Minerva Neurosciences by 12.2% in the 3rd quarter. BlackRock Inc. now owns 2,448,326 shares of the biopharmaceutical company’s stock worth $30,727,000 after acquiring an additional 266,623 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Minerva Neurosciences by 22.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 126,840 shares of the biopharmaceutical company’s stock valued at $1,592,000 after buying an additional 23,059 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Minerva Neurosciences during the 3rd quarter valued at about $1,510,000. Dimensional Fund Advisors LP grew its holdings in Minerva Neurosciences by 302.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,572,618 shares of the biopharmaceutical company’s stock valued at $19,736,000 after buying an additional 1,181,577 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Minerva Neurosciences by 35.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 152,576 shares of the biopharmaceutical company’s stock valued at $1,914,000 after buying an additional 40,346 shares in the last quarter. 76.16% of the stock is owned by institutional investors.

NERV stock opened at $7.76 on Tuesday. Minerva Neurosciences Inc has a twelve month low of $5.80 and a twelve month high of $12.95.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.01). As a group, analysts predict that Minerva Neurosciences Inc will post -1.4 earnings per share for the current fiscal year.

A number of research analysts have weighed in on NERV shares. ValuEngine lowered Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. BidaskClub lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday, December 20th. Finally, Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Friday, January 4th.

ILLEGAL ACTIVITY NOTICE: “Rhumbline Advisers Purchases 13,332 Shares of Minerva Neurosciences Inc (NERV)” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/rhumbline-advisers-purchases-13332-shares-of-minerva-neurosciences-inc-nerv/2918510.html.

Minerva Neurosciences Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Recommended Story: How is a buy-side analyst different from a sell-side analyst?

Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences Inc (NASDAQ:NERV).

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.